Phase 1/2 trial of oral EPI-7386 (masofaniten) in combination with enzalutamide (Enz) compared to Enz alone in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase 1 (P1) results and phase 2 (P2) design Meeting Abstract
| Authors: | Kyriakopoulos, C.; Chatta, G. S.; Laccetti, A. L.; Iannotti, N.; Sokolova, A.; Hotte, S. J.; Tutrone, R. F.; Markowski, M. C.; Nordquist, L. T.; Pili, R.; Saad, F.; Zhang, J.; Villaluna, K.; Younginger, B.; Le Moigne, R.; Cesano, A. |
| Abstract Title: | Phase 1/2 trial of oral EPI-7386 (masofaniten) in combination with enzalutamide (Enz) compared to Enz alone in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase 1 (P1) results and phase 2 (P2) design |
| Meeting Title: | 2024 ASCO Genitourinary Cancers Symposium |
| Keywords: | 261-492-2769; 613-225-2782; 261-566-9263; 283-2494-5577-2829-12292; 613-225-325; 261-492-3532-9726 |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2024 Jan 25-27 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-02-01 |
| Language: | English |
| ACCESSION: | WOS:001266676900281 |
| DOI: | 10.1200/JCO.2024.42.4_suppl.141 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 141 -- Source: Wos |
